Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 8/20 | 0.38 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.37 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.36 |
| ▸ | MC4R | P32245 | 1/20 | 0.36 |
| ▸ | TOP2A | P11388 | 1/20 | 0.35 |
| ▸ | MAT2A | P31153 | 1/20 | 0.35 |
| ▸ | FYN | P06241 | 1/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15411396 | 0.92 | MGAT2 (0.37) | ELANEEGLN2ADORA2AMC4RTOP2A | |
| SCHEMBL15410874 | 0.91 | EGLN2 (0.40) | ELANEEGLN2ADORA2AMALT1MC4R | |
| SCHEMBL15412140 | 0.90 | MALT1 (0.36) | ELANEADORA2AMALT1MAT2AAURKA | |
| SCHEMBL15412214 | 0.88 | ADORA2A (0.39) | ELANEEGLN2ADORA2AMALT1MC4R | |
| SCHEMBL15411629 | 0.88 | ELANE (0.49) | ELANEEGLN2ADORA2AMC4RTOP2A | |
| SCHEMBL15425572 | 0.88 | ELANE (0.36) | ELANEADORA2AMALT1MAT2AAURKA | |
| SCHEMBL15412416 | 0.88 | MALT1 (0.35) | ELANEADORA2AMALT1LRRK2 | |
| SCHEMBL18043803 | 0.88 | KMT2A (0.45) | ELANEEGLN2ADORA2AMALT1MAT2A | |
| SCHEMBL15411167 | 0.88 | ELANE (0.38) | ELANEEGLN2ADORA2AMALT1MC4R | |
| SCHEMBL15412053 | 0.88 | EGLN2 (0.38) | ELANEEGLN2ADORA2AMC4RTOP2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2872509-B1 | INHIBITION OF ENZYMES | CHIESI FARMA SPA (IT) | 2016-09-14 | — | — | EP | claimed |
| US-9199984-B2 | Inhibition of enzymes | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-12-01 | — | — | US | claimed |
| EP-2872509-A1 | INHIBITION OF ENZYMES | Chiesi Farmaceutici S.p.A. (IT) | 2015-05-20 | — | — | EP | claimed |
| WO-2014009425-A1 | INHIBITION OF ENZYMES | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-01-16 | — | — | WO | claimed |
| US-20140018345-A1 | INHIBITION OF ENZYMES | CHIESI FARMACEUTICI S.P.A (IT) | 2014-01-16 | — | — | US | claimed |
| EP-2872509-B1 | INHIBITION OF ENZYMES | CHIESI FARMA SPA (IT) | 2016-09-14 | — | — | EP | disclosed |
| EP-2872509-B1 | INHIBITION OF ENZYMES | CHIESI FARMA SPA (IT) | 2016-09-14 | — | — | EP | disclosed |
| US-9199984-B2 | Inhibition of enzymes | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-12-01 | — | — | US | disclosed |
| US-9199984-B2 | Inhibition of enzymes | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-12-01 | — | — | US | disclosed |
| US-9199984-B2 | Inhibition of enzymes | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-12-01 | — | — | US | disclosed |
| EP-2872509-A1 | INHIBITION OF ENZYMES | Chiesi Farmaceutici S.p.A. (IT) | 2015-05-20 | — | — | EP | disclosed |
| US-20140018345-A1 | INHIBITION OF ENZYMES | CHIESI FARMACEUTICI S.P.A (IT) | 2014-01-16 | — | — | US | disclosed |
| WO-2014009425-A1 | INHIBITION OF ENZYMES | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-01-16 | — | — | WO | disclosed |
| WO-2014009425-A1 | INHIBITION OF ENZYMES | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-01-16 | — | — | WO | disclosed |
| US-20140018345-A1 | INHIBITION OF ENZYMES | CHIESI FARMACEUTICI S.P.A (IT) | 2014-01-16 | — | — | US | disclosed |
| US-20140018345-A1 | INHIBITION OF ENZYMES | CHIESI FARMACEUTICI S.P.A (IT) | 2014-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018345-A1 | INHIBITION OF ENZYMES | SERPINB1, ELANE, MPO | ELANE 2/4885EGLN2 760/4885ADORA2A 1511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.